Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis - Nguyen, Thao H. P.; Hokstad, Ingrid; Fagerland, Morten Wang; Mollnes, Tom Eirik; Hollan, Ivana; Feinberg, Mark W.; Hjeltnes, Gunnbjørg; Eilertsen, Gro Ø.; Mikkelsen, Knut; Agewall, Stefan (PloS one, 2022)
Keywords: Analysis; Antirheumatic agents; Antirheumatic Agents - pharmacology; Antirheumatic Agents - therapeutic use; Arteriosclerosis; Arthritis; Arthritis, Rheumatoid - drug therapy; Atherogenesis; Atherosclerosis; Autoimmune diseases; Biology and Life Sciences; Biomarkers; Blood & organ donations; Blood Sedimentation; C-reactive protein; C-Reactive Protein - analysis; Cardiology; Cardiovascular disease; Cardiovascular diseases; Care and treatment; Cholesterol; Cholesterol, HDL - blood; Cholesterol, LDL - blood; Clinical medicine; Complement; Complement activation; Complement Activation - drug effects; Complement Membrane Attack Complex - analysis; Diagnosis; Dosage and administration; Drug Administration Schedule; Drug Therapy, Combination; Erythrocyte sedimentation rate; Erythrocytes; Ethylenediaminetetraacetic acids; Female; Health sciences; Heart diseases; Hospitals; Humans; Inflammation; Interleukin; Interleukin 6; Interleukin-6 - blood; Laboratories; Male; Medicine; Medicine and Health Sciences; Methotrexate; Methotrexate - pharmacology; Methotrexate - therapeutic use; Middle Aged; Patients; Prevention; Reduction; Rheumatoid arthritis; Risk factors; Treatment Outcome; Tumor necrosis factor inhibitors; Tumor Necrosis Factor Inhibitors - pharmacology; Tumor Necrosis Factor Inhibitors - therapeutic use; Norway; United States--US; Massachusetts